Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
Mori et al., Journal of Microbiology, Immunology and Infection, doi:10.1016/j.jmii.2020.09.003
Mori et al., Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia, Journal of Microbiology, Immunology and Infection, doi:10.1016/j.jmii.2020.09.003
Oct 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small case study of 5 patients in Japan showing improvement with HCQ+AZ+ciclesonide.
Mori et al., 5 Oct 2020, peer-reviewed, 3 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal of Microbiology, Immunology and Infection (2021) 54, 109e112 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.e-jmii.com Short Communication Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia Nobuaki Mori a,*, Mitsuya Katayama a, Shigenari Nukaga b a Department of General Internal Medicine and Infectious Diseases, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan b Department of Respiratory Medicine, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan Received 13 May 2020; received in revised form 24 August 2020; accepted 9 September 2020 Available online 5 October 2020 KEYWORDS COVID-19; SARS-CoV-2; Pneumonia; Hydroxychloroquine; Azithromycin; Ciclesonide; Therapy; Reverse transcription-PCR Abstract No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy. Copyright ª 2020, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit